36C25026P0251 Bilaterally Signed.pdf

This document is a Solicitation/Contract/Order for Commercial Products and Commercial Services issued by the Department of Veterans Affairs (VA) to Adaptive Biotechnologies Corporation for CloneSEQ Measurable Residual Disease (MRD) testing services. The contract is valued at $243,750.00 for an estimated 125 tests during the one-year performance period from 12/29/2025 to 12/28/2026.

The contract requires Adaptive Biotechnologies to provide FDA-cleared, next-generation sequencing (NGS)-based MRD testing for blood and bone marrow samples from patients diagnosed with multiple myeloma, chronic lymphocytic leukemia, and B-cell acute lymphoblastic leukemia. Testing will be conducted at the contractor's CLIA-certified and CAP-accredited reference laboratory, with full interpretation and reporting of results to VA clinicians. The testing is clinically essential for monitoring disease progression, determining treatment efficacy, and assessing patient outcomes during cancer therapy. Invoices will be submitted monthly in arrears, and the results will be delivered electronically within five business days of specimen submission.